High Dose Glargine Alters the Expression Profiles of MicroRNAs in Pancreatic Cancer Cells

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2012 Jun 13

PMID 22690071

Citations 10

Authors

Wei-Guang Li

Yao-Zong Yuan

Min-Min Qiao

Yong-Ping Zhang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the effect of high dose glargine on the expression profiles of microRNAs in human pancreatic cancer cells.

Methods: Real-time polymerase chain reaction array (RT-PCR) was applied to investigate miRNAs differentially expressed in Sw1990 cells treated with or without 100 IU/L glargine. Stem-loop RT-PCR was used to conﬁrm the results of the array assay in Sw1990 and Panc-1 cells. The effects of miR-95 on cell growth, apoptosis, invasion and migration abilities were respectively examined by CCK8 assay, apoptosis assay, Matrigel invasion and migration assay in Sw1990 and Panc-1 cells. Nude mice xenograft models with Sw1990 cells were built to investigate pancreatic cancer growth in vivo after transfection by the lentivirus pGLV3-GFP- miR-95.

Results: Ten miRNAs were significantly up-regulated and 2 miRNAs down-regulated in glargine treated Sw1990 cells when compared with non-treated cells (2.48-fold changes on average, P < 0.01). miR-95, miR-134 and miR-34c-3p are the top three miRNAs regulated by glargine (3.65-fold, 2.67-fold and 2.60-fold changes respectively, P < 0.01) in Sw1990 cells. Stem-loop RT-PCR confirmed that high dose glargine up-regulated the expression of miR-95 and miR-134 in both Sw1990 and Panc-1 cells. The most obvious change is the apparent increase of miR-95. Forced expression of miR-95 significantly increased cell proliferation (Sw1990: 2.510 ± 0.129 vs 2.305 ± 0.187, P < 0.05; Panc-1: 2.439 ± 0.211 vs 2.264 ± 0.117, P < 0.05), invasion (Sw1990: 67.90 ± 12.33 vs 47.30 ± 5.89, P < 0.01; Panc-1: 37.80 ± 8.93 vs 30.20 ± 5.14, P < 0.01), migration (Sw1990: 101 ± 6.00 vs 51.20 ± 8.34, P < 0.01; Panc-1: 91.80 ± 9.22 vs 81.50 ± 7.47, P < 0.01) and inhibited cell apoptosis (Sw1990: 22.05% ± 1.92% vs 40.32% ± 1.93%, P < 0.05; Panc-1: 20.17% ± 0.85% vs 45.60% ± 1.43%, P < 0.05) when compared with paired negative controls, whereas knockdown of miR-95 obtained the opposite effect. Nude mice xenograft models confirmed that miR-95 promoted the growth of pancreatic cancer in vivo when compared with negative control (tumor volume: 373.82 ± 23.67 mL vs 219.69 ± 17.82 mL, P < 0.05).

Conclusion: These observations suggested that modulation of miRNA expression may be an important mechanism underlying the biological effects of glargine.

Citing Articles

In Vivo Stable Allogenic Cartilage Regeneration in a Goat Model Based on Immunoisolation Strategy Using Electrospun Semipermeable Membranes.

Huo Y, Bai B, Zheng R, Sun Y, Yu Y, Wang X Adv Healthc Mater. 2023; 12(13):e2203084.

PMID: 36789972 PMC: 11469122. DOI: 10.1002/adhm.202203084.

Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.

Lauber C, Correia N, Trumpp A, Rieger M, Dolnik A, Bullinger L Sci Rep. 2020; 10(1):12761.

PMID: 32728112 PMC: 7391693. DOI: 10.1038/s41598-020-69691-8.

Insulin glargine affects the expression of , , and genes in colon and liver of diabetic rats.

Juarez-Vazquez C, Gurrola-Diaz C, Vargas-Guerrero B, Dominguez-Rosales J, Rodriguez-Ortiz J, Barros-NuneZ P Iran J Basic Med Sci. 2018; 21(5):489-494.

PMID: 29922429 PMC: 6000212. DOI: 10.22038/IJBMS.2018.24867.6185.

Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Taucher V, Mangge H, Haybaeck J Cell Oncol (Dordr). 2016; 39(4):295-318.

PMID: 27060060 DOI: 10.1007/s13402-016-0275-7.

Development of a circulating miRNA assay to monitor tumor burden: From mouse to man.

Greystoke A, Ayub M, Rothwell D, Morris D, Burt D, Hodgkinson C Mol Oncol. 2015; 10(2):282-91.

PMID: 26654130 PMC: 4750526. DOI: 10.1016/j.molonc.2015.10.004.

References

Zhang Y, Li M, Wang H, Fisher W, Lin P, Yao Q . Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2008; 33(4):698-709. PMC: 2933040. DOI: 10.1007/s00268-008-9833-0. View

Bandres E, Agirre X, Ramirez N, Zarate R, Garcia-Foncillas J . MicroRNAs as cancer players: potential clinical and biological effects. DNA Cell Biol. 2007; 26(5):273-82. DOI: 10.1089/dna.2006.0544. View

Baserga R . The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res. 1995; 55(2):249-52. View

Li G, Barrett E, Wang H, Chai W, Liu Z . Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology. 2005; 146(11):4690-6. DOI: 10.1210/en.2005-0505. View

Xiao J, Jing Z, Ellinor P, Liang D, Zhang H, Liu Y . MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med. 2011; 9:159. PMC: 3189884. DOI: 10.1186/1479-5876-9-159. View

Rong H, Liu T, Yang K, Yang H, Wu D, Liao C . MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res. 2010; 45(1):92-5. DOI: 10.1016/j.jpsychires.2010.04.028. View

Waldman S, Terzic A . Translating MicroRNA discovery into clinical biomarkers in cancer. JAMA. 2007; 297(17):1923-5. DOI: 10.1001/jama.297.17.1923. View

Currie C, Poole C, Gale E . The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52(9):1766-77. DOI: 10.1007/s00125-009-1440-6. View

L Bartels C, Tsongalis G . MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009; 55(4):623-31. DOI: 10.1373/clinchem.2008.112805. View

10.

Wiggins J, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D . Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010; 70(14):5923-30. PMC: 2913706. DOI: 10.1158/0008-5472.CAN-10-0655. View

11.

Warshaw A, Fernandez-Del Castillo C . Pancreatic carcinoma. N Engl J Med. 1992; 326(7):455-65. DOI: 10.1056/NEJM199202133260706. View

12.

Blum W, Past R, Kessler U, Hoeflich A, Meiler B, Kiess W . Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment. J Clin Endocrinol Metab. 1995; 80(4):1207-13. DOI: 10.1210/jcem.80.4.7536202. View

13.

Nakata K, Ohuchida K, Mizumoto K, Kayashima T, Ikenaga N, Sakai H . MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery. 2011; 150(5):916-22. DOI: 10.1016/j.surg.2011.06.017. View

14.

Crawford M, Brawner E, Batte K, Yu L, Hunter M, Otterson G . MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008; 373(4):607-12. DOI: 10.1016/j.bbrc.2008.06.090. View

15.

Boominathan L . The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One. 2010; 5(5):e10615. PMC: 2868896. DOI: 10.1371/journal.pone.0010615. View

16.

Michell N, Dent S, Langman M, Eggo M . Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation. Growth Factors. 1997; 14(4):269-77. DOI: 10.3109/08977199709021525. View

17.

Nicoloso M, Spizzo R, Shimizu M, Rossi S, Calin G . MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009; 9(4):293-302. DOI: 10.1038/nrc2619. View

18.

Schickel R, Boyerinas B, Park S, Peter M . MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008; 27(45):5959-74. DOI: 10.1038/onc.2008.274. View

19.

Baranwal S, Alahari S . miRNA control of tumor cell invasion and metastasis. Int J Cancer. 2009; 126(6):1283-90. PMC: 2950784. DOI: 10.1002/ijc.25014. View

20.

Gerich J . Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin. 2004; 20(1):31-7. DOI: 10.1185/030079903125002711. View